Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes

Kidney International

Volumn 73, Issue 12, 2008, Pages 1419-1425

  Persson, F ^a   Rossing, P ^a   Schjoedt, K J ^a   Juhl, T ^a   Tarnow, L ^a   Stehouwer, C D A ^b   Schalkwijk, C ^b   Boomsma, F ^c   Frandsen, E ^d   Parving, H H ^e,f  

^a STENO DIABETES CENTER   (Denmark)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e Mental Health Services CPH   (Denmark)

^f AARHUS UNIVERSITY   (Denmark)

Author keywords

Albuminuria; Aliskiren; Diabetic nephropathy; Renin inhibition; Renin angiotensin system; Type 2 diabetes

Indexed keywords

ALBUMIN; ALDOSTERONE; ALISKIREN; ANGIOTENSIN I; ANGIOTENSIN II; BIOLOGICAL MARKER; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; FUROSEMIDE;

ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG INHIBITION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 43449139264     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.68     Document Type: Article

References (38)

1. Parving H-H, Mauer M, Ritz E. Diabetic Nephropathy, Chap. 36. In: Brenner BM (ed). Brenner and Rector's The Kidney, 8th edn, Elsevier: Philadelphia, USA, 2008, pp 1265-1298.
2. Parving H-H, Lehnert H, Bröchner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
3. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
4. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
5. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
6. Rossing K, Schjoedt KJ, Smidt UM et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-2112.
7. Rossing K, Jacobsen P, Pietraszek L et al. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003; 26: 2268-2274.
8. Rossing K, Christensen PK, Jensen BR et al. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002; 25: 95-100.
9. Rossing K, Schjoedt KJ, Jensen BR et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68: 1190-1198.
10. de Zeeuw D, Remuzzi G, Parving H-H et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927.
11. Rossing P, Hommel E, Smidt UM et al. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994; 37: 511-516.
12. Stanton A, Jensen C, Nussberger J et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-1143.
13. Gradman AH, Schmieder RE, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018.
14. van Paassen P, de Zeeuw D, Navis G et al. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol Dial Transplant 2000; 15: 637-643.
15. Fisher NDL, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005; 16: 592-599.
16. Nussberger J, Wuerzner G, Jensen C et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39: E1-E8.
17. Andersen S, Jacobsen P, Tarnow L et al. Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Nephrol Dial Transplant 2003; 18: 293-297.
18. Chan JCN, Cockram CS, Nicholls MG et al. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetics associated with hypertension: one year analysis. BMJ 1992; 305: 981-985.
19. Parving H-H, Lewis JB, Lewis E et al. Aliskiren in the evaluation of proteinuria in diabetes (AVOID). J Am Soc Nephrol 2007; 18: 574A.
20. Kelly D, Zhang Y, Moe G et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50: 2398-2404.
21. Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995; 8: 876-883.
22. Morelli E, Loon N, Meyer TW et al. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990; 39: 76-82.
23. Remuzzi A, Ruggenenti P, Mosconi L et al. Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. J Nephrol 1993; 6: 36-43.
24. Reddi AS, Ramamurthi R, Miller M et al. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Med Metab Biol 1991; 45: 119-131.
25. Langham RG, Kelly DJ, Cox AJ et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002; 45: 1572-1576.
26. Nguyen G, Delarue F, Burckle C et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427.
27. Saris JJ, 't Hoen PA, Garrelds IM et al. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 2006; 48: 564-571.
28. Jan Danser AH, Batenburg WW, van Esch JHM. Prorenin and the (pro)renin receptor-an update. Nephrol Dial Transplant 2007; 22: 1288-1292.
29. Ichihara A, Suzuki F, Nakagawa T et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006; 17: 1950-1961.
30. Schefe JH, Menk M, Reinemund J et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006; 99: 1355-1366.
31. Luetscher JA, Kramer FB, Wilson DM et al. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985; 312: 1412-1417.
32. Persson F, Rossing P, Hovind P et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes 2006; 55: 3550-3555.
33. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
34. Derkx FH, de Bruin RJ, van Gool JM et al. Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity. Clin Chem 1996; 42: 1051-1063.
35. Derkx FH, van den Meiracker AH, Fischli W et al. Nonparallel effects of renin inhibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects: an assay-related artifact. Am J Hypertens 1991; 4: 602-609.
36. Poulsen K, Jorgensen J. An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocrinol Metab 1974; 39: 816-825.
37. Millar JA, Leckie BJ, Morton JJ et al. A microassay for active and total renin concentration in human plasma based on antibody trapping. Clin Chim Acta 1980; 101: 5-15.
38. Teerlink T, Nijveldt RJ, de Jong S et al. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002; 303: 131-137.